ImmuCell Q2 2025 preliminary sales up 18% YoY to $6.4M; backlog cleared

IMMUCELL CORP /DE/

2025-Q2 EPS reported $0.22 revenue$14,512,054

Preliminary Q2 2025 product sales $6.4M, up 18% from $5.5M in Q2 2024.
Twelve-month sales ended June 30, 2025 were $28.3M, up 22% YoY from $23.2M.
Order backlog reduced to under $100k as of June 30, 2025, down from $3.4M on May 6.
Evaluating additional capacity investments to increase production capacity to ~$40M per year.
Conference call scheduled for August 15, 2025 to discuss full Q2 2025 financial results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.